Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Zetagen Therapeutics

Request full access

Biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions

Syracuse, United StatesFounded 2015Biotech & Life Sciences

About Zetagen Therapeutics

Zetagen is a biotechnology company specializing in the development of osteoinductive platform technologies aimed at promoting bone growth. The company operates in the orthopedic market, focusing on creating products that activate a novel molecular pathway to stimulate bone regeneration. Zetagen's innovative approach has the potential to revolutionize the treatment of bone-related injuries, procedures, and diseases, offering better, safer, and more cost-effective solutions for patients, healthcare providers, and payors.

The company's primary clients include orthopedic surgeons, hospitals, and healthcare systems that require advanced solutions for bone repair and regeneration. Zetagen's business model revolves around the commercialization of its proprietary small molecule-based technology, generating revenue through product sales and potential licensing agreements.

Zetagen's leadership team, led by CEO Joe Loy, brings extensive experience in the spine and orthopedic industries, with a proven track record of driving growth and successful acquisitions. The company is committed to continuous learning and innovation, striving to deliver optimal therapeutic solutions that benefit patients, investors, and society.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
69.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Jan 2026 $0 — Excell Partners ↗
SERIES B✓Equity / VC Nov 2025 $13M $52M JSTAR Capital Investments ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Zetagen Therapeutics website traffic

Latest recorded traffic for Zetagen Therapeutics is 1.5K monthly website visits, down 25% over the last three months. Zetagen Therapeutics's team grew 12.5% over the past year.

Latest monthly visits1.5K 3-month web change-25% 1-year team growth+12.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Zetagen Therapeutics in the Syracuse ecosystem

Live from Dealroom

The Zetagen Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • MedTech Innovator
  • National Cancer Institute (NCI)

Series A4 investors entered at this stage

  • National Institutes of Health
  • Consolidated Investment Group
  • New York Ventures
  • JSTAR Capital Investments

Series B and later1 investor entered at this stage

  • Excell Partners

Other known investors3 additional known investors

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States85.7%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Zetagen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zetagen Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.